Filing Flows › Companies › Xenon Pharmaceuticals › Timeline
Xenon Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+2.2% to $39.17
Xenon Pharmaceuticals (XENE) stock rose 2% over the last 252 sessions, to $39.17. On the way it reported 3 quarters, its insiders filed 1 open-market trade and 2 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Aug 28, 2026 | Form 144 | Form 144: Christopher Kenney plans to sell $438K | −3.2% (−3.0% vs SPY) | −2.5% (−2.8% vs SPY) | −52.3% (−51.8% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Steven Gannon plans to sell $641K | −1.6% (−1.3% vs SPY) | −2.9% (−2.9% vs SPY) | −8.5% (−7.1% vs SPY) |
| Aug 11, 2026 | Insider sale | Gannon Steven sold $641K | −1.6% (−1.3% vs SPY) | −2.9% (−2.9% vs SPY) | −8.5% (−7.1% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 4.4% | +0.4% (+0.5% vs SPY) | +1.5% (+1.1% vs SPY) | −6.2% (−6.7% vs SPY) |
| Jun 3, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.9% (−1.3% vs SPY) | −4.0% (−0.2% vs SPY) | +12.4% (+12.6% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 2.3% | −4.5% (−4.2% vs SPY) | −4.7% (−5.9% vs SPY) | −12.5% (−13.0% vs SPY) |
| Apr 13, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.3% (+0.1% vs SPY) | −2.6% (−5.9% vs SPY) | −6.4% (−13.7% vs SPY) |
| Mar 12, 2026 | 8-K | Material definitive agreement | −4.7% (−4.1% vs SPY) | −4.8% (−3.9% vs SPY) | +1.2% (−2.0% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: missed the EPS estimate by -8.7% | +0.8% (+1.3% vs SPY) | −3.5% (−2.3% vs SPY) | +22.0% (+28.9% vs SPY) |
| Dec 1, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.5% (−1.6% vs SPY) | +2.3% (+1.8% vs SPY) | +3.0% (+2.4% vs SPY) |
Insiders’ record here
In the year on the chart, Xenon Pharmaceuticals' insiders reported 0 open-market buys ($0) and 1 sale ($641K).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Xenon Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.